Research on application of dexamethasone intravitreal implant in ocular fundus diseases related to macular edema

Abstract

The intravitreal dexamethasone (DEX) implant is a drug sustained-release system formulated in a biodegradable copolymer, which contains the ingredient of dexamethasone.At present, the intravitreal dexamethasone implant (Ozurdex) is approved in Europe and USA for the treatment of macular edema related to central retinal vein occlusion, branch retinal vein occlusion, diabetic retinopathy and non-infectious uveitis.In addition, the treatment of macular edema secondary to other ocular fundus diseases related with inflammation such as wet age-related macular degeneration, vasoproliferative retinal tumors, Coats disease, radiation maculopathy, retinitis pigmentosa, and pars plana vitrectomy has been reported.This paper is aimed to provide a review of the research and application of DEX intravitreal implant in the treatment of macular edema in recent years, and provide a new option for the treatment of these clinical refractory diseases. \n \n \nKey words: \nEdema, macular;\xa0Dexamethasone;\xa0Implant, intravitreal